Automated analysis of corneal nerve tortuosity in diabetes: implications for neuropathy detection.


Journal

Clinical & experimental optometry
ISSN: 1444-0938
Titre abrégé: Clin Exp Optom
Pays: United States
ID NLM: 8703442

Informations de publication

Date de publication:
07 2022
Historique:
entrez: 30 6 2022
pubmed: 1 7 2022
medline: 6 7 2022
Statut: ppublish

Résumé

There is potential benefit in analysing corneal nerve tortuosity as a marker for assessment and progression of systemic diabetic neuropathy. The aim of this work was to determine whether tortuosity significantly differs in participants with type 1 (T1DM) and type 2 (T2DM) diabetes compared to controls and whether tortuosity differed according to neuropathy status. Corneal nerves of 164 participants were assessed across T1DM, T2DM and control groups. Images of corneal nerves were captured via in vivo corneal confocal microscopy. Diabetic neuropathy status was examined using the Total Neuropathy Score (TNS). Tortuosity was assessed with Cfibre v0.097. Results were compared between groups with a linear mixed model accounting for location of image and controlling for age, producing Tortuosity Factor (TF), an estimate of the marginal means of each group. Tortuosity was significantly reduced in the T1DM group compared to controls (TF = 0.241, 95%CI = 0.225-0.257 vs. TF = 0.272, 95%CI = 0.252-0.292; mean difference = -0.031, p = 0.02) and in the T2DM group compared to controls (TF = 0.261, 95%CI = 0.244-0.278 vs. TF = 0.289, 95%CI = 0.270-0.308; mean difference = -0.029, p = 0.03). Tortuosity did not significantly differ between participants with T1DM and T2DM accounting for age and TNS (TF = 0.240, 95%CI = 0.215-0.265 vs. 0.269, 95%CI = 0.244-0.293, mean difference = -0.029, p = 0.11). Tortuosity was significantly reduced in participants with neuropathy (TNS≥2) compared to participants with no neuropathy (TNS< 2) (TF = 0.248, 95%CI = 0.231-0.265 vs. TF = 0.272, 95%CI = 0.260-0.283; mean difference = -0.024, p = 0.03). Tortuosity is significantly reduced in participants with T1DM and T2DM compared to age matched controls and in participants with neuropathy compared to those without neuropathy.

Sections du résumé

CLINICAL RELEVANCE
There is potential benefit in analysing corneal nerve tortuosity as a marker for assessment and progression of systemic diabetic neuropathy.
BACKGROUND
The aim of this work was to determine whether tortuosity significantly differs in participants with type 1 (T1DM) and type 2 (T2DM) diabetes compared to controls and whether tortuosity differed according to neuropathy status.
METHODS
Corneal nerves of 164 participants were assessed across T1DM, T2DM and control groups. Images of corneal nerves were captured via in vivo corneal confocal microscopy. Diabetic neuropathy status was examined using the Total Neuropathy Score (TNS). Tortuosity was assessed with Cfibre v0.097. Results were compared between groups with a linear mixed model accounting for location of image and controlling for age, producing Tortuosity Factor (TF), an estimate of the marginal means of each group.
RESULTS
Tortuosity was significantly reduced in the T1DM group compared to controls (TF = 0.241, 95%CI = 0.225-0.257 vs. TF = 0.272, 95%CI = 0.252-0.292; mean difference = -0.031, p = 0.02) and in the T2DM group compared to controls (TF = 0.261, 95%CI = 0.244-0.278 vs. TF = 0.289, 95%CI = 0.270-0.308; mean difference = -0.029, p = 0.03). Tortuosity did not significantly differ between participants with T1DM and T2DM accounting for age and TNS (TF = 0.240, 95%CI = 0.215-0.265 vs. 0.269, 95%CI = 0.244-0.293, mean difference = -0.029, p = 0.11). Tortuosity was significantly reduced in participants with neuropathy (TNS≥2) compared to participants with no neuropathy (TNS< 2) (TF = 0.248, 95%CI = 0.231-0.265 vs. TF = 0.272, 95%CI = 0.260-0.283; mean difference = -0.024, p = 0.03).
CONCLUSIONS
Tortuosity is significantly reduced in participants with T1DM and T2DM compared to age matched controls and in participants with neuropathy compared to those without neuropathy.

Identifiants

pubmed: 35772934
doi: 10.1080/08164622.2021.1940875
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

487-493

Auteurs

Jacob Klisser (J)

Prince of Wales Clinical School, University of New South Wales, Sydney, Australia.

Shyam Sunder Tummanapalli (SS)

School of Optometry & Vision Science, University of New South Wales, Sydney, Australia.

Juno Kim (J)

School of Optometry & Vision Science, University of New South Wales, Sydney, Australia.

Jeremy Chung Bo Chiang (JCB)

School of Optometry & Vision Science, University of New South Wales, Sydney, Australia.

Vincent Khou (V)

School of Optometry & Vision Science, University of New South Wales, Sydney, Australia.
Centre for Eye Health, University of New South Wales, Sydney, Australia.

Tushar Issar (T)

Prince of Wales Clinical School, University of New South Wales, Sydney, Australia.

Thomas Naduvilath (T)

School of Optometry & Vision Science, University of New South Wales, Sydney, Australia.

Ann M Poynten (AM)

Department of Endocrinology, Prince of Wales Hospital, Sydney, Australia.

Maria Markoulli (M)

School of Optometry & Vision Science, University of New South Wales, Sydney, Australia.

Arun V Krishnan (AV)

Prince of Wales Clinical School, University of New South Wales, Sydney, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH